Brown Brothers Harriman & Co. Has $150,000 Stock Position in Laboratory Co. of America Holdings (NYSE:LH)

Brown Brothers Harriman & Co. boosted its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 46.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 653 shares of the medical research company’s stock after buying an additional 207 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Laboratory Co. of America were worth $150,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LH. Quantbot Technologies LP acquired a new position in shares of Laboratory Co. of America during the third quarter worth $596,000. CreativeOne Wealth LLC raised its position in Laboratory Co. of America by 19.7% in the third quarter. CreativeOne Wealth LLC now owns 1,488 shares of the medical research company’s stock valued at $332,000 after purchasing an additional 245 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Laboratory Co. of America by 14.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,689 shares of the medical research company’s stock valued at $3,953,000 after purchasing an additional 2,234 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Laboratory Co. of America by 9.2% during the third quarter. Public Sector Pension Investment Board now owns 3,572 shares of the medical research company’s stock worth $798,000 after purchasing an additional 300 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new position in shares of Laboratory Co. of America in the third quarter valued at approximately $447,000. Institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling

In other news, CEO Adam H. Schechter sold 6,121 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total value of $1,497,319.02. Following the completion of the sale, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. This represents a 6.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Amy B. Summy sold 758 shares of the firm’s stock in a transaction dated Friday, March 28th. The shares were sold at an average price of $231.67, for a total transaction of $175,605.86. Following the transaction, the executive vice president now directly owns 5,302 shares in the company, valued at $1,228,314.34. The trade was a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,258 shares of company stock worth $3,753,177 in the last quarter. Insiders own 0.85% of the company’s stock.

Laboratory Co. of America Stock Down 0.0 %

Shares of NYSE:LH opened at $232.63 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $258.59. The business’s 50 day simple moving average is $244.45 and its two-hundred day simple moving average is $234.86. The firm has a market cap of $19.47 billion, a P/E ratio of 26.38, a PEG ratio of 1.71 and a beta of 1.12.

Laboratory Co. of America (NYSE:LH) last issued its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, research analysts forecast that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Thursday, February 27th were issued a $0.72 dividend. The ex-dividend date of this dividend was Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.24%. Laboratory Co. of America’s dividend payout ratio is presently 32.65%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Bank of America boosted their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and upped their price target for the company from $260.00 to $265.00 in a research report on Tuesday, January 7th. Morgan Stanley raised their price objective on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Piper Sandler upped their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, Jefferies Financial Group raised their price target on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $269.92.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.